Clinical Trial Update: Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update describes the combination of pembrolizumab and lenvatinib for high-grade serous cancers of the fallopian tube, ovary, or periton…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Carcinoma of the Fallopian Tube
• High-grade Serous Carcinoma of the Peritoneum
• High-grade Serous Ovarian Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING